论文部分内容阅读
目的:探讨乙肝抗纤汤联合干扰素治疗乙肝后肝纤维化的临床疗效。方法:选择我院自2014年1月到2015年6月收治的70例乙型肝炎患者为研究对象,按照随机数字表法分成观察组和对照组,对照组采用临床常规治疗,并采用干扰素治疗,观察组在对照组治疗方法基础上联合应用乙肝抗纤汤治疗,对两组治疗后的临床疗效进行比较。结果:观察组有效率为88.6%,显著高于对照组有效率65.7%(P<0.05)。结论:乙肝抗纤维汤联合干扰素治疗乙肝后肝纤维化,能够显著提高临床治疗效果,改善患者临床预后,值得向临床推广。
Objective: To investigate the clinical efficacy of Hepatitis B and Anti-fibang combined with interferon in treating posthepatitic liver fibrosis. Methods: Seventy patients with hepatitis B who were treated in our hospital from January 2014 to June 2015 were selected as study subjects and divided into observation group and control group according to random number table. The control group was treated with routine therapy and treated with interferon Treatment, observation group in the control group based on the combination of hepatitis B anti-fibangolic therapy, the clinical efficacy of the two groups were compared. Results: The effective rate in observation group was 88.6%, which was significantly higher than that in control group (65.7%, P <0.05). Conclusion: Hepatitis B anti-fiber soup combined with interferon in the treatment of post-hepatitis B liver fibrosis can significantly improve the clinical therapeutic effect and improve the clinical prognosis of patients, worthy of clinical promotion.